Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 104

1.

New therapies for relapsed castration-resistant prostate cancer based on peptide analogs of hypothalamic hormones.

Schally AV, Block NL, Rick FG.

Asian J Androl. 2015 Nov-Dec;17(6):925-8. doi: 10.4103/1008-682X.152819.

2.

Gonadotropin-releasing hormone: an update review of the antagonists versus agonists.

Van Poppel H, Klotz L.

Int J Urol. 2012 Jul;19(7):594-601. doi: 10.1111/j.1442-2042.2012.02997.x. Review.

5.
6.

Singapore Cancer Network (SCAN) Guidelines for the Management of Advanced Castrate-Resistant Prostate Cancer.

Singapore Cancer Network (SCAN) Genitourinary Cancer Workgroup..

Ann Acad Med Singapore. 2015 Oct;44(10):397-405.

7.

[Treatment of carcinoma of the prostate with analogs of LHRH].

Rubio Herrera MA, Calle Fernández JR.

Rev Clin Esp. 1986 Nov;179(8):407-11. Spanish. No abstract available.

PMID:
2951782
8.

The effect of androgen deprivation therapy on fasting serum lipid and glucose parameters.

Yannucci J, Manola J, Garnick MB, Bhat G, Bubley GJ.

J Urol. 2006 Aug;176(2):520-5.

PMID:
16813881
9.

Somatostatin analogs and disease control in castration-resistant prostate cancer: different biological behavior? Case series and review of the literature.

D'Angelillo RM, Greco C, Fiore M, Ippolito E, Eolo Trodella L, Iurato A, Molfese E, Ramella S, Trodella L.

Tumori. 2014 May-Jun;100(3):249-53. doi: 10.1700/1578.17192.

PMID:
25076233
10.

Luteinizing hormone (LH)-releasing hormone agonist reduces serum adrenal androgen levels in prostate cancer patients: implications for the effect of LH on the adrenal glands.

Nishii M, Nomura M, Sekine Y, Koike H, Matsui H, Shibata Y, Ito K, Oyama T, Suzuki K.

J Androl. 2012 Nov-Dec;33(6):1233-8. doi: 10.2164/jandrol.112.016493.

PMID:
22492843
11.

Hormonal therapy of prostate cancer.

Debruyne F.

Semin Urol Oncol. 2002 Aug;20(3 Suppl 1):4-9. Review.

PMID:
12198632
12.

Phase I, dose-escalation study of the targeted cytotoxic LHRH analog AEZS-108 in patients with castration- and taxane-resistant prostate cancer.

Liu SV, Tsao-Wei DD, Xiong S, Groshen S, Dorff TB, Quinn DI, Tai YC, Engel J, Hawes D, Schally AV, Pinski JK.

Clin Cancer Res. 2014 Dec 15;20(24):6277-83. doi: 10.1158/1078-0432.CCR-14-0489.

13.

A phase III extension trial with a 1-arm crossover from leuprolide to degarelix: comparison of gonadotropin-releasing hormone agonist and antagonist effect on prostate cancer.

Crawford ED, Tombal B, Miller K, Boccon-Gibod L, Schröder F, Shore N, Moul JW, Jensen JK, Olesen TK, Persson BE.

J Urol. 2011 Sep;186(3):889-97. doi: 10.1016/j.juro.2011.04.083.

PMID:
21788033
14.

Degarelix (firmagon) for prostate cancer.

[No authors listed]

Med Lett Drugs Ther. 2009 Oct 19;51(1323):82-3. Review. No abstract available.

PMID:
19838145
15.

[Recruiting participants - study of therapy of CRPC].

[No authors listed]

Aktuelle Urol. 2014 Sep;45(5):354-5. doi: 10.1055/s-0034-1393918. German. No abstract available.

PMID:
25275687
16.

[Total androgen blockade].

Namiki M, Mizokami A.

Nihon Rinsho. 2002 Dec;60 Suppl 11:193-8. Review. Japanese. No abstract available.

PMID:
12599570
17.

[Hormonal treatments of prostate cancer].

Kuhn JM.

Rev Prat. 1990 Nov 1;40(25):2357-62. French. No abstract available.

PMID:
2124721
19.

Hormone ablation therapy: lightening the load for today's prostate cancer patient.

Matthews PA.

Urol Nurs. 2007 Feb;27 Suppl:3-11. Review.

PMID:
17474637
20.

Physiologic basis of endocrine therapy for prostatic cancer.

McConnell JD.

Urol Clin North Am. 1991 Feb;18(1):1-13. Review.

PMID:
1899494
Items per page

Supplemental Content

Support Center